中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
Structural perspective of class B1 GPCR signaling

文献类型：期刊论文

作者Cong, Zhaotong2; Liang, Yi-Lynn3; Zhou, Qingtong2; Darbalaei, Sanaz1,4,5; Zhao, Fenghui1,5; Feng, Wenbo2; Zhao, Lihua5; Xu, H. Eric4,5; Yang, Dehua1,3,4,5; Wang, Ming-Wei1,2,3,4,5,6
刊名TRENDS IN PHARMACOLOGICAL SCIENCES
出版日期2022-04-01
卷号43期号:4页码:321-334
ISSN号0165-6147
DOI10.1016/j.tips.2022.01.002
通讯作者Wang, Ming-Wei(mwwang@simm.ac.cn)
英文摘要Class B1 G protein-coupled receptors (GPCRs) play important roles in human physiology and disease pathology. Using cryo-electron microscopy (cryo-EM) and X-ray crystallography, the 3D structures of all 15 members of this receptor subfamily have been determined in recent years at the near-atomic level. Although they share many structural commonalities, they show distinct features in terms of ligand recognition and receptor activation. In-depth structural analyses have yielded valuable insights into the N termini of both peptide hormones and cognate receptors, the outward movement of transmembrane helix 6 (TM6), the allosteric modulation sites located in the transmembrane domain (TMD), and the constitutive signaling bias mediated by receptor splice variants. These provide new directions for the design of better therapeutic agents, thereby making these targets more druggable.
WOS关键词FACTOR CRF RECEPTOR ; GLP-1 RECEPTOR ; TRANSMEMBRANE DOMAIN ; PARATHYROID-HORMONE ; SPLICE VARIANTS ; ACTIVATION ; RECOGNITION ; PEPTIDE ; ISOFORM ; BINDING
资助项目National Natural Science Foundation of China[81872915] ; National Natural Science Foundation of China[82073904] ; National Natural Science Foundation of China[32071203] ; National Natural Science Foundation of China[81773792] ; National Natural Science Foundation of China[81973373] ; National Natural Science Foundation of China[21704064] ; National Science and Technology Major Project of China - Key New Drug Creation and Manufacturing Program[2018ZX09735-001] ; National Science and Technology Major Project of China - Key New Drug Creation and Manufacturing Program[2018ZX09711002-002-005] ; National Science and Technology Major Project of China - Key New Drug Creation and Manufacturing Program[2021ZD0203400] ; National Key Basic Research Program of China[2018YFA0507000] ; Ministry of Science and Technology of China[2018YFA0507002] ; Shanghai Municipal Science and Technology Commission Major Project[2019SHZDZX02] ; Strategic Priority Research Program of ChineseAcademy of Sciences[XDB37030103] ; Novo Nordisk-CAS Research Fund[NNCAS-2017-1-CC] ; Shanghai Science and Technology Development Funds[18ZR1447800] ; Shanghai Science and Technology Development Funds[18431907100] ; Young InnovatorAssociation of CAS[2018325] ; SA-SIBS Scholarship Program
WOS研究方向Pharmacology & Pharmacy
语种英语
出版者ELSEVIER SCIENCE LONDON
WOS记录号WOS:000776138400007
源URL[http://119.78.100.183/handle/2S10ELR8/299839]  
专题中国科学院上海药物研究所
通讯作者Wang, Ming-Wei
作者单位1.Chinese Acad Sci, Natl Ctr Drug Screening, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China
2.Fudan Univ, Sch Basic Med Sci, Dept Pharmacol, Shanghai 200032, Peoples R China
3.Res Ctr Deepsea Bioresources, Sanya 572025, Hainan, Peoples R China
4.Univ Chinese Acad Sci, Beijing 100049, Peoples R China
5.Chinese Acad Sci, Key Lab Receptor Res, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China
6.ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai 201210, Peoples R China
推荐引用方式
GB/T 7714		 Cong, Zhaotong,Liang, Yi-Lynn,Zhou, Qingtong,et al. Structural perspective of class B1 GPCR signaling[J]. TRENDS IN PHARMACOLOGICAL SCIENCES,2022,43(4):321-334.
APA Cong, Zhaotong.,Liang, Yi-Lynn.,Zhou, Qingtong.,Darbalaei, Sanaz.,Zhao, Fenghui.,...&Wang, Ming-Wei.(2022).Structural perspective of class B1 GPCR signaling.TRENDS IN PHARMACOLOGICAL SCIENCES,43(4),321-334.
MLA Cong, Zhaotong,et al."Structural perspective of class B1 GPCR signaling".TRENDS IN PHARMACOLOGICAL SCIENCES 43.4(2022):321-334.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。